Search

Tedizolid (TZD) is an oxazolidinone anti-methicillin-resistant Staphylococcus aureus (MRSA) drug. Linezolid (LZD), another oxazolidinone, has been shown to have an anti-inflammatory effect. TZD has been shown to exhibit an anti-inflammatory effect in a murine model of hematogenous pulmonary infection. In this study, we further investigated the anti-inflammatory effect of TZDs using a carrageenan-induced rat footpad edema model. TZD was administered at 0, 10, 20, and 40 mg/kg to the carrageenan-induced rat footpad edema model, and the edema rate was measured over time up to 9 h later. The area under the time curve of the edema rate profile (AUC edema0→9) decreased in a TZD dose-dependent manner. In addition, the correlation between AUC edema0→9 and the area under the time curve of free TZD plasma concentration (f AUC blood) obtained from the pharmacokinetic study of TZD in the carrageenan-induced rat footpad edema model was examined. f AUC blood and AUC edema0→9 showed a good negative correlation. These results indicate that TZD suppresses carrageenan-induced footpad edema and that TZD exerts its anti-inflammatory effects in a plasma concentration-dependent manner. [ABSTRACT FROM AUTHOR]